Full Press Release Details
Lexaria files Additional New Patent Pendings
Kelowna, BC December 14, 2015 - Lexaria Corp.
(LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces it has
initiated the simultaneous filing of two new U.S. provisional patent
applications at the U.S. Patent and Trademark Office.
These applications are in addition to the Company s earlier
2014 and 2015 family of provisional patent application filings, and build on the
innovations earlier established. The Company has filed the new patent
applications in order to establish broader intellectual property protection
regarding its innovative method of combining certain useful payload molecules
with certain edible substances within food and beverage compositions. Benefits
of the innovation include improved taste and aroma experiences as well as higher
absorption rates of the payload molecules.
The new edible substances are base ingredients in many
commercial food and beverage formulations, involving products as diverse as
carbonated and non-carbonated beverages; fruit or vegetable flavored beverages;
dairy based beverages; sports and energy drinks; flavored water; pastas; breads,
grains; spices and more. The applications also encompass pharmaceutical
compositions that include tablets, pills, capsules, liquids, gels and syrups.
Specifically, the Company has protected improved food and
beverage compositions with lipophilic active agents and methods of their
manufacture using tapioca starch or other related compounds, as well as improved
ready-to-drink beverage compositions with lipophilic active agents and methods
of their manufacture using gum Arabic or other related compounds.
The new patent applications are applicable to the same payload
molecules as the Company s earlier patent applications: cannabinoids, nicotine,
non-steroidal anti-inflammatory drugs (acetylsalicylic acid, ibuprophen,
acetaminophen, diclofenac, indomethacin, and piroxicam), and vitamins.
Lexaria is confident it has now done all it can to expand and
preserve the intellectual property value of its underlying technology, and its
application into a wide variety of products within both the food and the
pharmaceutical industries. The Company remains fully committed to its consumer
products division, however this underlying technology provides Lexaria its most
significant competitive advantages in the consumer marketplace, and will soon
provide the foundation for future technology licensing and partnering efforts.
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The company searches
for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit www.lexariaenergy.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to:
achieving sales through any retail distribution channels such as dispensaries or
traditional retailers. Such forward-looking statements are estimates reflecting
the Company's best judgment based upon current information and involve a number
of risks and uncertainties, and there can be no assurance that other factors
will not affect the accuracy of such forward-looking statements. Access to
capital, or lack thereof, is a major risk and there is no assurance that the
Company will be able to raise required working capital. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that the medical marijuana, hemp oil sector, or alternative health
businesses will provide any benefit to Lexaria, or that the Company will
experience any growth through participation in these sectors. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will not need to attempt to raise additional capital. There is no assurance that
any planned corporate activity, business venture, or initiative will be pursued,
or if pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. There is no assurance that the cannabinoid/lipid
infusion technology will provide any increase in bioavailability to any
individual person. There is no assurance that any patent application in the USA
or any other nation or under any treaty will result in the award of an actual
patent; nor that an award of any actual patent will protect against challenges
from unknown third parties. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patent-pending technology will
in fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). ViPovaTM
products and Lexaria Energy products are not intended to diagnose, treat, cure
or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.